Form 4: Director Robert B. Carter Acquires Quest Diagnostics Stock

Quest Diagnostics Director Robert B. Carter acquired 1,142 shares of common stock through an award of restricted stock units.

Summary

• Robert B. Carter, a Director at Quest Diagnostics Inc., acquired 1,142 shares of common stock on May 20, 2026.
• The acquisition was made through an award of restricted stock units.
• Following this transaction, Mr. Carter beneficially owns 3,853 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine stock award to a director rather than a discretionary purchase or sale that might indicate a stronger market sentiment.

Positives

• Director acquisition of company stock can signal confidence in the company's future prospects.
• The acquisition was made at a price of $0, indicating it was an award rather than a purchase, which is a common form of executive compensation.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider stock awards, such as restricted stock units, are a common component of executive and director compensation across the healthcare diagnostics industry, aligning leadership interests with shareholder value.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively, suggesting insider confidence in the company's performance.
• Employees: This filing does not directly impact employees, but it is part of the broader compensation structure for leadership.

Key Dates

Keywords

Quest Diagnostics, DGX, Form 4, Insider Trading, Stock Acquisition, Restricted Stock Units, Director, Beneficial Ownership